Literature DB >> 29350913

Environmentally Triggerable Retinoic Acid-Inducible Gene I Agonists Using Synthetic Polymer Overhangs.

Christian R Palmer, Max E Jacobson, Olga Fedorova, Anna M Pyle, John T Wilson.   

Abstract

Retinoic acid-inducible gene I (RIG-I) is a cytosolic pattern recognition receptor (PRR) that potently activates antiviral innate immunity upon recognition of 5' triphosphorylated double-stranded RNA (pppRNA). Accordingly, RNA ligands of the RIG-I pathway have recently emerged as promising antiviral agents, vaccine adjuvants, and cancer immunotherapeutics. However, RIG-I is expressed constitutively in virtually all cell types, and therefore administration of RIG-I agonists causes risk for systemic inflammation and possible dose-limiting toxicities. Here, we establish proof-of-concept and initial design criteria for pppRNA prodrugs capable of activating the RIG-I pathway in response to specific environmental stimuli. We show that covalent conjugation of poly(ethylene glycol) (PEG) to the 3' end of the complementary strand, i.e., on the same side but opposite strand as the 5' triphosphate group, can generate a synthetic overhang that prevents RIG-I activation. Additionally, conjugation of PEG through a cleavable linker-here, a reducible disulfide bond-allows for removal of the synthetic overhang and restoration of immunostimulatory activity. Furthermore, we demonstrate that blockade of RIG-I activation via synthetic overhangs is dependent on PEG molecular weight, with a critical molecular weight between 550 and 1000 Da required to inhibit activity. Additionally, we demonstrate that blockade of RIG-I activity is conjugation site-dependent, as ligation of PEG to the opposite end of the RNA did not influence ligand activity. Collectively, this work demonstrates that conjugation of synthetic polymer overhangs to pppRNA through cleavable linkers is a viable strategy for the development of environmentally triggerable RIG-I-targeting prodrugs.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29350913      PMCID: PMC6407425          DOI: 10.1021/acs.bioconjchem.7b00697

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   4.774


  60 in total

Review 1.  Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple.

Authors:  F Q Schafer; G R Buettner
Journal:  Free Radic Biol Med       Date:  2001-06-01       Impact factor: 7.376

Review 2.  Toll-like receptor control of the adaptive immune responses.

Authors:  Akiko Iwasaki; Ruslan Medzhitov
Journal:  Nat Immunol       Date:  2004-10       Impact factor: 25.606

3.  Topical application of imiquimod and associated fever in children.

Authors:  Alexandre Campanelli; Joachim Krischer; Jean-Hilaire Saurat
Journal:  J Am Acad Dermatol       Date:  2005-01       Impact factor: 11.527

4.  5'-Triphosphate RNA is the ligand for RIG-I.

Authors:  Veit Hornung; Jana Ellegast; Sarah Kim; Krzysztof Brzózka; Andreas Jung; Hiroki Kato; Hendrik Poeck; Shizuo Akira; Karl-Klaus Conzelmann; Martin Schlee; Stefan Endres; Gunther Hartmann
Journal:  Science       Date:  2006-10-12       Impact factor: 47.728

Review 5.  Pathogen recognition and innate immunity.

Authors:  Shizuo Akira; Satoshi Uematsu; Osamu Takeuchi
Journal:  Cell       Date:  2006-02-24       Impact factor: 41.582

Review 6.  Human models of innate immunity: local and systemic inflammatory responses.

Authors:  C Fiuza; A F Suffredini
Journal:  J Endotoxin Res       Date:  2001

Review 7.  Therapeutic potential of Toll-like receptor 9 activation.

Authors:  Arthur M Krieg
Journal:  Nat Rev Drug Discov       Date:  2006-06       Impact factor: 84.694

Review 8.  The role of glutathione in cancer.

Authors:  Ganesaratnam K Balendiran; Rajesh Dabur; Deborah Fraser
Journal:  Cell Biochem Funct       Date:  2004 Nov-Dec       Impact factor: 3.685

9.  Complexation of lipofectamine and cholesterol-modified DNA sequences studied by single-molecule fluorescence techniques.

Authors:  Anca Margineanu; Steven De Feyter; Sergey Melnikov; Damien Marchand; Arthur van Aerschot; Piet Herdewijn; Satoshi Habuchi; Frans C De Schryver; Johan Hofkens
Journal:  Biomacromolecules       Date:  2007-10-25       Impact factor: 6.988

10.  First in human phase I trial of 852A, a novel systemic toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced cancer.

Authors:  Arkadiusz Z Dudek; Carla Yunis; Lester I Harrison; Sandeep Kumar; Ronald Hawkinson; Sarah Cooley; John P Vasilakos; Kevin S Gorski; Jeffrey S Miller
Journal:  Clin Cancer Res       Date:  2007-12-01       Impact factor: 12.531

View more
  7 in total

Review 1.  Biomaterials for vaccine-based cancer immunotherapy.

Authors:  Rui Zhang; Margaret M Billingsley; Michael J Mitchell
Journal:  J Control Release       Date:  2018-10-09       Impact factor: 9.776

Review 2.  Bioinspired nucleic acid structures for immune modulation.

Authors:  Cameron Louttit; Kyung Soo Park; James J Moon
Journal:  Biomaterials       Date:  2019-06-19       Impact factor: 12.479

Review 3.  Immunostimulatory biomaterials to boost tumor immunogenicity.

Authors:  Oluwaseyi T Shofolawe-Bakare; Larry D Stokes; Mehjabeen Hossain; Adam E Smith; Thomas A Werfel
Journal:  Biomater Sci       Date:  2020-09-02       Impact factor: 6.843

4.  Harnessing the Activation of RIG-I Like Receptors to Inhibit Glioblastoma Tumorigenesis.

Authors:  Francesca Bufalieri; Irene Basili; Lucia Di Marcotullio; Paola Infante
Journal:  Front Mol Neurosci       Date:  2021-07-08       Impact factor: 5.639

Review 5.  Harnessing RIG-I and intrinsic immunity in the tumor microenvironment for therapeutic cancer treatment.

Authors:  David L Elion; Rebecca S Cook
Journal:  Oncotarget       Date:  2018-06-22

6.  Knockdown of IGF-1R Triggers Viral RNA Sensor MDA5- and RIG-I-Mediated Mitochondrial Apoptosis in Colonic Cancer Cells.

Authors:  Shu-Qing Wang; Xiang-Yu Yang; Xin-Feng Yu; Shu-Xiang Cui; Xian-Jun Qu
Journal:  Mol Ther Nucleic Acids       Date:  2019-02-20       Impact factor: 8.886

7.  Structural Optimization of Polymeric Carriers to Enhance the Immunostimulatory Activity of Molecularly Defined RIG-I Agonists.

Authors:  Max E Jacobson; Kyle W Becker; Christian R Palmer; Lucinda E Pastora; R Brock Fletcher; Kathryn A Collins; Olga Fedorova; Craig L Duvall; Anna M Pyle; John T Wilson
Journal:  ACS Cent Sci       Date:  2020-10-26       Impact factor: 14.553

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.